Antibody-Drug Conjugate Shows Striking First-Line Results in HER2-Driven Lung Cancer

Lung cancer researchers in China have reported some of the strongest real-world signals yet that a targeted antibody-drug conjugate could transform the first-line treatment of a rare but stubborn molecular subtype of non-small cell lung cancer. In a multicenter retrospective study published in BMC Cancer, patients with advanced NSCLC harboring HER2 mutations or amplification who received trastuzumab deruxtecan, known as T-DXd, as their initial systemic therapy experienced a median progression-free survival of 15.7 months, roughly double the benefit seen with conventional chemotherapy-based regimens. The findings, drawn from six medical centers of the Chinese PLA General Hospital between January 2016 and December 2025, arrive at a moment when the treatment landscape for HER2-altered lung cancer is shifting faster than at any point in its history.

HER2, the same receptor made famous in breast cancer biology, functions in lung cancer as a rare but consequential driver gene. Non-small cell lung cancer accounts for about 85 percent of all lung cancers, yet five-year survival for advanced-stage disease remains below 10 percent. In Chinese patients, HER2 mutations occur in roughly 2 to 4 percent of NSCLC cases and amplifications in about 1.7 percent. Until recently, the standard first-line approach for these patients was platinum-based chemotherapy, with or without immunotherapy, an approach that historically delivered a median progression-free survival of only around 4.4 months, extended to about 8.2 months when immunotherapy was added. Antibodies, pan-HER tyrosine kinase inhibitors, and the earlier antibody-drug conjugate T-DM1 had all shown limited efficacy in prior studies.

The new study enrolled 69 patients, of whom 45 had only HER2 alterations and 24 carried both HER2 and EGFR alterations simultaneously. All alterations were confirmed by next-generation sequencing of tumor tissue or plasma, since no validated FISH criteria exist for HER2 amplification in NSCLC in China. The cohort reflected the classic epidemiological profile of HER2-driven disease: a median age of 59 years, a slight female predominance, adenocarcinoma histology in nearly all cases, and a majority of never-smokers. Most patients had good performance status at the start of therapy, and the most common metastatic sites were the lung, bone, and malignant pleural effusion.

The molecular architecture of the tumors was dominated by exon 20 insertion mutations in the HER2 kinase domain, with the A775_G776insYVMA insertion being the single most frequent variant. TP53 was the most common co-mutated gene, present in nearly 38 percent of the HER2-only group and over 62 percent of the co-alteration group. Among patients with HER2-EGFR co-alterations, the EGFR mutations were overwhelmingly the exon 21 L858R substitution, with a smaller number of exon 19 deletions. This molecular detail matters because HER2 activation is a well-established mechanism of resistance to EGFR inhibitors, raising a long-standing question about whether primary dual-pathway activation undermines EGFR-targeted therapy from the outset.

The headline result concerns the eight patients with only HER2 alterations who received first-line T-DXd. Seven of the eight achieved a partial response, yielding an objective response rate of 85.7 percent and a disease control rate of 100 percent. The median time to first response was a remarkably rapid 1.7 months, and the median progression-free survival of 15.7 months compared with 7.6 months for chemotherapy-based regimens, 7.0 months for chemotherapy plus the pan-HER inhibitor pyrotinib, and just 4.4 months for pan-HER tyrosine kinase inhibitor monotherapy with afatinib or dacomitinib. No grade 3 or higher treatment-related adverse events were observed in the T-DXd group, with all events limited to grade 1 or 2 and predominantly hematological in nature.

The authors were careful to frame these comparisons as exploratory rather than definitive. Treatment allocation was neither randomized nor protocol-driven; decisions reflected tumor burden, patient preference, financial considerations, and drug accessibility, and T-DXd only became available in China after its October 2024 approval for previously treated patients. Selection bias is a real concern, since patients with more aggressive disease may have been steered toward chemotherapy while fitter patients with strong preferences based on the DESTINY-Lung05 trial data opted for the antibody-drug conjugate. Sensitivity analyses excluding the 13 patients with unresectable stage III disease, and separately excluding co-alterations defined only by plasma testing, largely preserved the original findings, lending some robustness to the central signal.

The subgroup analyses added further nuance. Among patients with pure HER2 mutations, T-DXd produced a median progression-free survival of 16.8 months with an objective response rate of 85.7 percent, and the advantage held within the exon 20 insertion subgroup specifically. TP53 co-mutation emerged as an independent adverse prognostic factor: patients without TP53 mutations had a median progression-free survival of 8.7 months versus 7.2 months for those with the co-mutation, and after multivariate adjustment the hazard ratio of 0.35 reached statistical significance. The authors suggest that the same TP53-driven genome doubling and resistance mechanisms documented in EGFR-mutant disease may operate in HER2-altered tumors as well. PD-L1 expression, by contrast, showed no significant association with outcome, though incomplete testing limited that analysis.

The story was markedly less encouraging for the 24 patients whose tumors carried both HER2 and EGFR alterations. Fifteen of them received EGFR tyrosine kinase inhibitor monotherapy, achieving a median progression-free survival of only 9.7 months with an objective response rate of 40 percent. Notably, third-generation inhibitors such as osimertinib performed no better than first-generation drugs, and the 10.2-month median for third-generation agents falls well short of the outcomes typically reported for EGFR-mutant lung cancer without HER2 co-alterations. The authors hypothesize that HER2, with its constitutively open active conformation, serves as a preferred dimerization partner for EGFR, creating a signaling network with greater compensatory potential that allows tumors to escape single-pathway inhibition. A small group of three patients treated with EGFR inhibitor plus chemotherapy fared numerically better at 13.6 months, but the sample is far too small to draw conclusions.

The study lands amid a rapidly evolving therapeutic field. In February 2026, the FDA approved zongertinib, a highly selective oral HER2 inhibitor, for first-line treatment of HER2 tyrosine kinase domain-mutant advanced NSCLC, based on phase Ib data showing a 76 percent response rate and a 14.4-month median progression-free survival in treatment-naive patients. A phase III trial comparing zongertinib directly with chemotherapy is underway. The authors stress that their poor results with older pan-HER inhibitors such as afatinib and dacomitinib should not be extrapolated to these newer selective agents. Whether T-DXd or an oral HER2 inhibitor should occupy the first-line position, and how the two classes might be sequenced, remains an open question that only head-to-head prospective trials can answer.

For now, the study offers the first sizable real-world comparison of first-line T-DXd against conventional therapies in HER2-altered lung cancer, and its message is twofold. For patients whose tumors carry only HER2 alterations, the antibody-drug conjugate delivered response rates and survival durations never before seen in this setting, with no severe treatment-related toxicity in this small cohort, though the established risk of interstitial lung disease seen in larger trials demands continued vigilance. For the neglected subgroup with HER2-EGFR co-alterations, current targeted options remain inadequate, and the authors argue that HER2-directed antibody-drug conjugates, alone or combined with EGFR inhibitors, represent a promising untested frontier. The ongoing DESTINY-Lung04 trial, which compares T-DXd with chemoimmunotherapy in the first line, will be the decisive test of whether these real-world signals survive the scrutiny of randomization.

Subject of Research: First-line treatment outcomes with trastuzumab deruxtecan and conventional therapies in HER2-altered advanced non-small cell lung cancer

Article Title: First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status

Article References: First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status. (n.d.). https://doi.org/10.1186/s12885-026-16688-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16688-7

Keywords: NSCLC, HER2, EGFR, trastuzumab deruxtecan, antibody-drug conjugate, targeted therapy, progression-free survival, co-alteration, tyrosine kinase inhibitor, lung cancer, precision oncology, real-world evidence